CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.
  
  LEARNING OBJECTIVES

  • Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to evaluate and select available front-line options.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors and consider the implications of these findings for clinical decision making for newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
  • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease related factors impact the selection and sequencing of therapy for patients with relapsed/refractory CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies employed in the management of CLL.
  • Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL and, where applicable, refer eligible patients for clinical trial participation.

  CE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
  In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIANS
  Audio program: The University of Nebraska Medical Center designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  Video program: The University of Nebraska Medical Center designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  NURSES
  Audio Program: The University of Nebraska Medical Center designates this activity for 2 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
  Video Program: The University of Nebraska Medical Center designates this activity for 2 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This CE activity consists of an audio component. To receive credit, the participant should review the CE information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/UNMCPanPacific22CLL/CME or ResearchToPractice.com/UNMCPanPacific22CLL/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/UNMCPanPacific22CLL/Video.
  
  Video Program: This CE activity consists of a video component. To receive credit, the participant should review the CE information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/UNMCPanPacific22CLL/Video/CME or ResearchToPractice.com/UNMCPanPacific22CLL/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/UNMCPanPacific22CLL.
  
  CONTENT VALIDATION AND DISCLOSURES
  As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
  
  All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
  
  This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
  
  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
  
  FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  
  
  Danielle Brander, MD
  Assistant Professor of Medicine
  Director, CLL and Lymphoma Clinical Research Program
  Duke University Medical Center
  Durham, North Carolina
  
  Advisory Committee: AbbVie Inc, Genentech, a member of the Roche Group, Pfizer Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ArQule Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Catapult Therapeutics, CATO SMS, Celgene Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Juno Therapeutics, a Celgene Company, MEI Pharma Inc, Newave Pharmaceutical Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Nonrelevant Financial Relationship: CLL Society (expert medical council), NCCN (panel member).
  
  Matthew S Davids, MD, MMSc
  Associate Professor of Medicine
  Harvard Medical School
  Director of Clinical Research
  Division of Lymphoma
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Ono Pharmaceutical Co Ltd, Pharmacyclics LLC, an AbbVie Company, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Surface Oncology, TG Therapeutics Inc; Honoraria: Aptitude Health, Curio Science; Nonrelevant Financial Relationship: Bio Ascend.
  
  Anthony R Mato, MD, MSCE
  Associate Attending
  Director, Chronic Lymphocytic Leukemia Program
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements and Data and Safety Monitoring Board/Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Celgene Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Genmab, Johnson & Johnson Services Inc, Nurix Therapeutics Inc, Octapharma Plasma, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Genmab, Johnson & Johnson Services Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Octapharma Plasma, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc.
  
  William G Wierda, MD, PhD
  Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey
  Section Chief, Chronic Lymphocytic Leukemia
  Center Medical Director
  Department of Leukemia, Division of Cancer Medicine
  Executive Medical Director, Inpatient Medical Services
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose:
  Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by an educational grant from Genentech, a member of the Roche Group.
  
  Release date: November 2, 2022
  Expiration date: November 2, 2023
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.